Latest From Yeshiva University
A review of biopharma start-up dealmaking and financing activity from April through June 2017, based on data from Strategic Transactions, showed that fundraising activity more than doubled compared with the first quarter.
In the second quarter of 2012, start-up companies raised a total of $556 million across all industries. Most of that financing – $439.8 million – went to the biopharma sector. Cancer was the most prevalent therapeutic area for alliances. There were just four start-up acquisitions – two each in the biopharma and medical device industries.
START-UP’s monthly update on technology transfer deals—licensing agreements between companies and universities or other research institutions—in the fields of in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical equipment & supplies.
A roundup of recent medtech mergers & acquisitions, strategic alliances, and financings.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.